Classifying new anti-tuberculosis drugs: rationale and future perspectives

•The World Health Organization (WHO) 2016 guidelines for multidrug-resistant tuberculosis (MDR-TB) propose a regrouping of anti-TB drugs for the treatment of MDR-TB.•The classification of anti-TB drugs guides the clinician in designing an appropriate multidrug-/extensively drug-resistant TB regimen....

Full description

Saved in:

Bibliographic Details
Published in:	International journal of infectious diseases Vol. 56; no. C; pp. 181 - 184
Main Authors:	Tiberi, Simon, Scardigli, Anna, Centis, Rosella, D’Ambrosio, Lia, Muñoz-Torrico, Marcela, Salazar-Lezama, Miguel Ángel, Spanevello, Antonio, Visca, Dina, Zumla, Alimuddin, Migliori, Giovanni Battista, Caminero Luna, Jose A.
Format:	Journal Article
Language:	English
Published:	Canada Elsevier Ltd 01.03.2017 Elsevier
Subjects:	Anti-TB drugs Antitubercular Agents - classification Antitubercular Agents - therapeutic use Bedaquiline Biological Evolution Delamanid Drug Monitoring Fluoroquinolones Humans Infectious Disease Linezolid MDR/XDR-TB Microbial Sensitivity Tests Mycobacterium tuberculosis - drug effects Pulmonary/Respiratory Tuberculosis, Multidrug-Resistant - drug therapy World Health Organization Fluoroquinolones Linezolid MDR/XDR-TB Anti-TB drugs Delamanid Bedaquiline
ISSN:	1201-9712, 1878-3511, 1878-3511
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!